Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers

Ed Zhang is now CEO at Overland Pharmaceuticals, the Hillhouse-backed company he co-founded with Hua Mu in 2020 to bring innovative Western therapies to China. Zhang has served as interim CEO of the company, which has partnerships with ADC Therapeutics S.A. (NYSE:ADCT) and Allogene Therapeutics Inc. (NASDAQ:ALLO), since May 2021.

Overland also announced its appointment of John Maraganore and Peter Ho as strategic advisors. Since his retirement as CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Maraganore has also joined Arch Venture Partners, Ariadne Labs, Atlas Ventures, Beam Therapeutics Inc. (NASDAQ:BEAM), Brii Biosciences Ltd. (HKEX:2137), Hemab ApS, Pictet, RTW Investments, SalioGen Therapeutics Inc., Termeer Foundation and the n-Lorem Foundation in various capacities. Ho co-founded and was president of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160). ...